Sonnet BioTherapeutics Holdings, Inc. Logo

Sonnet BioTherapeutics Holdings, Inc.

Develops targeted cytokine therapies for cancer using a proprietary albumin-binding platform.

SONN | US

Overview

Corporate Details

ISIN(s):
US83548R1059
LEI:
Country:
United States of America
Address:
100 OVERLOOK CENTER, 8540 PRINCETON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company that develops targeted biologic medicines. The company's core technology is its proprietary Fully Human Albumin-Binding (FHAB™) platform, which utilizes a single-chain antibody fragment (scFv) that binds to the body's own albumin. This 'hitch-hiking' mechanism is designed to deliver cytokine payloads directly to tumor tissues, enhancing drug penetration, retention, and local activation. Sonnet's therapeutic goal is to convert immunologically 'cold' tumors into 'hot' tumors, thereby making them more responsive to treatment. The company's pipeline consists of several cytokine-derived therapeutic candidates in clinical development.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Sonnet BioTherapeutics Holdings, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Sonnet BioTherapeutics Holdings, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Sonnet BioTherapeutics Holdings, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tempest Therapeutics, Inc. Logo
Clinical-stage oncology company developing oral small molecule therapeutics to treat cancer.
United States of America
TPST
TENAX THERAPEUTICS, INC. Logo
Clinical-stage pharma developing novel therapies for cardiovascular and pulmonary diseases.
United States of America
TENX
Teva Pharmaceutical Industries Ltd. Logo
A leader in affordable generic drugs and innovative specialty treatments for complex diseases.
Israel
TEVA
Tevogen Bio Holdings Inc. Logo
Developing precision, off-the-shelf T cell therapies for cancer, infections, and neuro disorders.
United States of America
TVGN
TG THERAPEUTICS, INC. Logo
Commercializes B-cell therapies like BRIUMVI® for multiple sclerosis & autoimmune diseases.
United States of America
TGTX
Tharimmune, Inc. Logo
Clinical-stage biotech developing therapies for immunology, oncology, & opioid effects.
United States of America
THAR
THERAGEN ETEX CO.,LTD. Logo
A biotech firm offering gene analysis and developing personalized cancer drugs.
South Korea
066700
Theratechnologies Inc. Logo
Biopharma company commercializing therapies for multi-drug resistant HIV and lipodystrophy.
United States of America
THTX
Theravance Biopharma, Inc. Logo
Developing medicines for specialty respiratory and neurologic diseases like COPD.
United States of America
TBPH
TheraVet SA Logo
Belgium
ALVET

Talk to a Data Expert

Have a question? We'll get back to you promptly.